A universal recipient for protein production in eggs

鸡蛋中蛋白质生产的通用接受者

• 批准号: 6769353
• 负责人: BABETTE S HEYER
• 金额: $ 66.79万
• 依托单位: ORIGEN THERAPEUTICS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6769353
• 关键词: biological products; bioreactors; biotechnology; biotherapeutic agent; chickens; egg /ovum; genetic promoter element; genetically modified animals; method development; molecular cloning; protein biosynthesis; recombinant proteins

DESCRIPTION (provided by applicant): To date, chimeric chickens are made by injecting blastodermal cells or embryonic stem cells into the stage X embryo (recipient), but the frequency and level of chimerism is variable and unpredictable (Petitte et al., 1990; Petitte et al., 1993). We are developing a universal recipient that contributes minimally, so that the contribution of donor derived cells to the resulting chimera is constantly high and predictable. These high-grade chimeras can be used to produce biopharmaceutical proteins in chicken eggs as soon as the chimeras commence laying and before they transmit the gene encoding the biopharmaceutical protein to the next generation. In addition, these high-grade chimeras will allow the production of biopharmaceutical proteins if the transgene interferes with their ability to reproduce. The end point of this research is a robust system to produce high-grade chimeras in highly predictable way. Using this system biopharmaceutical proteins can be produced quickly, in a scalable system and at minimal cost.

描述（由申请人提供）：迄今为止，嵌合鸡是通过向X期胚胎（受体）注射胚皮细胞或胚胎干细胞制成的，但嵌合的频率和水平是可变的和不可预测的（Petitte et al., 1990; Petitte et al., 1993）。我们正在开发一种贡献最小的通用受体，这样供体来源的细胞对最终嵌合体的贡献就会一直很高，而且是可预测的。只要嵌合体开始产卵，并且在它们将编码生物制药蛋白的基因传递给下一代之前，这些高级嵌合体就可以用于在鸡蛋中生产生物制药蛋白。此外，如果转基因干扰了这些高级嵌合体的繁殖能力，这些嵌合体将允许生产生物制药蛋白。这项研究的目的是建立一个强大的系统，以高度可预测的方式生产高级嵌合体。使用该系统，可以在可扩展的系统中以最低的成本快速生产生物制药蛋白。